.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XG02_Carfilzomib.Carfilzomib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01X_OtherAntineoplasticAgents.L01XG02_Carfilzomib.Carfilzomib| name: | Carfilzomib |
| ATC code: | L01XG02 | route: | intravenous |
| n-compartments | 2 |
Carfilzomib is a selective proteasome inhibitor used predominantly in the treatment of multiple myeloma, a type of blood cancer. It is a second-generation irreversible inhibitor of the chymotrypsin-like activity of the 20S proteasome. Carfilzomib is approved for clinical use, particularly in patients with relapsed or refractory multiple myeloma.
Pharmacokinetic parameters described in adult patients with relapsed and/or refractory multiple myeloma following intravenous administration.
Ou, Y, et al., & Visich, J (2017). Population Pharmacokinetics and Exposure-Response Relationship of Carfilzomib in Patients With Multiple Myeloma. Journal of clinical pharmacology 57(5) 663–677. DOI:10.1002/jcph.850 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27925676
Costa, LJ, et al., & Stadtmauer, EA (2021). Phase 2 study of venetoclax plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma. Blood advances 5(19) 3748–3759. DOI:10.1182/bloodadvances.2020004146 PUBMED:https://pubmed.ncbi.nlm.nih.gov/34470049
Xu, XS, et al., & Clemens, PL (2020). Split First Dose Administration of Intravenous Daratumumab for the Treatment of Multiple Myeloma (MM): Clinical and Population Pharmacokinetic Analyses. Advances in therapy 37(4) 1464–1478. DOI:10.1007/s12325-020-01247-8 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32078124